Business Description
Medicenna Therapeutics Corp
NAICS : 325414
SIC : 3741
ISIN : CA58490H1073
Description
Financial Strength
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | No Debt | |||||
Equity-to-Asset | 0.6 | |||||
Interest Coverage | No Debt | |||||
Piotroski F-Score | 2/9 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 8.4 | |||||
3-Year EPS without NRI Growth Rate | 9.7 | |||||
3-Year FCF Growth Rate | 8.9 | |||||
3-Year Book Growth Rate | -52.8 | |||||
Future 3-5Y EPS without NRI Growth Rate | 24.71 |
Momentum Rank
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 56.52 | |||||
9-Day RSI | 55.41 | |||||
14-Day RSI | 53.34 | |||||
6-1 Month Momentum % | 48 | |||||
12-1 Month Momentum % | 469.23 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 9.43 | |||||
Quick Ratio | 9.43 | |||||
Cash Ratio | 8.85 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -9.2 | |||||
Shareholder Yield % | -11.72 |
Profitability Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
ROE % | -135.21 | |||||
ROA % | -93.91 | |||||
ROIC % | -28793.38 | |||||
ROC (Joel Greenblatt) % | -65196.43 | |||||
ROCE % | -74.89 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PB Ratio | 7.2 | |||||
Price-to-Tangible-Book | 7.17 | |||||
EV-to-EBIT | -7.05 | |||||
EV-to-EBITDA | -7.05 | |||||
EV-to-Forward-Revenue | 311.29 | |||||
EV-to-FCF | -8.75 | |||||
Price-to-Net-Current-Asset-Value | 7.17 | |||||
Price-to-Net-Cash | 7.96 | |||||
Earnings Yield (Greenblatt) % | -14.17 | |||||
FCF Yield % | -9.22 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Medicenna Therapeutics Corp Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil C$) | |||
EPS (TTM) (C$) | -0.37 | ||
Beta | 2.96 | ||
Volatility % | 200.81 | ||
14-Day RSI | 53.34 | ||
14-Day ATR (C$) | 0.128451 | ||
20-Day SMA (C$) | 2.027 | ||
12-1 Month Momentum % | 469.23 | ||
52-Week Range (C$) | 0.215 - 2.98 | ||
Shares Outstanding (Mil) | 76.43 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 2 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Medicenna Therapeutics Corp Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Medicenna Therapeutics Corp Stock Events
Event | Date | Price(C$) | ||
---|---|---|---|---|
No Event Data |
Medicenna Therapeutics Corp Frequently Asked Questions
What is Medicenna Therapeutics Corp(TSX:MDNA)'s stock price today?
When is next earnings date of Medicenna Therapeutics Corp(TSX:MDNA)?
Does Medicenna Therapeutics Corp(TSX:MDNA) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |